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Abstract Cognitive development in patients with tuber-
ous sclerosis complex is highly variable. Predictors in the
infant years would be valuable to counsel parents and to
support development. The aim of this study was to con-
firm factors that have been reported to be independently
correlated with cognitive development. 102 patients
included in this study were treated at the ENCORE-TSC
expertise center of the Erasmus Medical Center-Sophia
Children’s Hospital. Data from the first 24 months of life
were used, including details on epilepsy, motor
development and mutation status. Outcome was defined as
cognitive development (intellectual equivalent, IE) as
measured using tests appropriate to the patients age and
cognitive abilities (median age at testing 8.2 years, IQR
4.7–12.0). Univariable and multivariable regression anal-
yses were used. In a univariable analysis, predictors of
lower IE were: the presence of infantile spasms
(b = -18.3, p = 0.000), a larger number of antiepileptic
drugs used (b = -6.3, p = 0.000), vigabatrin not used as
first drug (b = -14.6, p = 0.020), corticosteroid treat-
ment (b = -33.2, p = 0.005), and a later age at which
the child could walk independently (b = -2.1,
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IE (b = 1.7, p = 0.000). In a multivariable analysis, only
age at seizure onset was significantly correlated to IE
(b = 1.2, p = 0.005), contributing to 28% of the variation
in IE. In our cohort, age at seizure onset was the only
variable that independently predicted IE. Factors predict-
ing cognitive development could aid parents and physi-
cians in finding the appropriate support and schooling for
these patients.
Keywords Tuberous sclerosis complex  Intelligence 
Intellectual disability  Epilepsy
Introduction
Tuberous sclerosis complex (TSC) is a genetic disorder,
with a large variation in symptoms between patients. Up to
90% of patients suffer from epilepsy, often starting in
infancy [2]. Two-thirds of patients have refractory seizures
[2, 12]. Cognitive function is highly variable in patients
with TSC. One-third of patients suffer from profound dis-
ability, while others have normal cognitive abilities
[4, 8, 14].
Several studies have attempted to unravel the causes
of this variation in cognitive development. Many studies
have shown that epilepsy is associated with delayed
development and impaired cognitive functioning [9]. In
previous studies, refractory seizures and infantile spasms
were correlated with lower cognitive functioning, while
older age at seizure onset and early treatment correlated
with better cognition [1, 5, 7, 8, 15]. Lesion burden on
brain MRI has also been correlated with cognition,
including the presence and number of cortical tubers
[11, 13].
Most of these correlations were identified using a
univariable analysis, between the factor of interest and
the cognitive abilities of the patient. While it is useful to
explore these correlations, it remains unclear what the
actual contribution of a specific variable to cognitive
functioning is, if the statistical method does not control
for other possible influencing factors. This is further
complicated by the rare nature of TSC; multivariable
regression models can only hold multiple variables if
sufficient patients are available to include in the analy-
ses. In a previous study where a multivariable model was
applied, the age at seizure onset was found to be the
only independent predictor of IE [7].
In a cohort of 102 children with TSC, we aimed to
confirm previously studied and identify new unstudied
characteristics collected in the first 24 months of life, that
are independent predictors for cognitive development later
in life.
Methods
Patients were selected from a retrospective follow-up
clinical database at the ENCORE-TSC expertise center at
the Erasmus Medical Center-Sophia Children’s Hospital.
Missing data were completed through correspondence with
physicians and other care providers. Of the total population
of 121 children treated at our clinic, data on cognitive
development were available for 102 children.
For all variables except intelligence equivalent (IE), data
from the first 24 months of life were used. Mutation analysis
was performed at the Department of Clinical Genetics of the
Erasmus Medical Center according to standard procedures,
using DNA extracted from peripheral blood. Success of the
first AED was categorized as ‘yes’ if the first AED caused a
seizure frequency decrease of 50% or more.
For all variables concerning epilepsy, children without
epilepsy were given the most beneficial outcome, since
previous studies have shown that the absence of epilepsy is
beneficial for cognitive development [9]. The variables
adjusted in patients without epilepsy are listed in Online
Resource 1. In addition, some values were adjusted in
children with epilepsy to include data from the first
24 months of life only; the variable ‘age at seizure onset’
was adjusted to 24 months (‘24’) in children with age at
onset after 24 months of age (16 children), and for the
variable ‘age of walking independently’, children who
were not able to walk were assigned the value of
24 months (‘24’) (17 children).
The outcome of all analyses was IE, measured by themost
reliable cognitive development testing based on the calendar
age and cognitive abilities of the child. TheDutch versions of
the following neuropsychological tests were used: Wechsler
Intelligence Scale for Children (WISC; n = 45), Bayley
Scales of Infant Development (BSID; n = 36), Wechsler
Preschool and Primary Scale of Intelligence (WPPSI;
n = 14), Snijders-Oomen Non-verbal Intelligence assess-
ment (SON-R; n = 5), Attachment, Interaction, Mastery,
Support (AIMS; n = 1) and Vineland Adaptive Behavior
Scales (VABS; n = 1). Since some of these psychological
tests measure development and not IQ, the value obtained
from all tests was called intelligence equivalent, IE [6].
Statistical analysis
For all continuous variables except IE, outliers were
removed by only allowing data values within the 5th and
95th percentile, and adjusting values outside this range to
the values of the 5th and 95th percentile. This adjusted
three data points for the variable ‘age of waling indepen-
dently’ and two for the ‘number of AEDs used’ variable.
Multiple imputation was used to eliminate missing values.
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Missing values were present for the following variables:
‘number of AEDs used’ (6), ‘treatment success of first
AED’ (7) and ‘age of walking independently’ (6).
IE values between children with and without epilepsy
were compared using an independent samples T test.
Univariable and multivariable regression models were
fitted with IE as outcome. Predictor variables in the
regression model were selected from previous studies
investigating the association between cognitive develop-
ment and disease characteristics in patients with TSC.
Variables with a Pearson correlation of [0.8 with other
variables were left out of the model to prevent colinearity.
This excluded the variable measuring the total number of
months in which seizures were present during the first
24 months of life. Beta’s with 95% confidence intervals
and corresponding p values were reported from the models.
A variable was considered to contribute significantly to IE
if the p value was below 0.05. The total amount of variance
in IE explained by the models was expressed with the R2.
IBM SPSS statistics version 22 was used for all analyses.
Results
Characteristics of 102 children included in this study
are shown in Table 1. IE was measured at a median age
of 8.2 years. The median IE of all children was 59
(IQR 39–78) and the median IE of children with
epilepsy was 55 (IQR 30–73). IE values are shown in
Fig. 1, for children with epilepsy and children without
epilepsy. Distribution of IE values of the total study
population was shifted towards lower values compared
to values in the general population. Median IE in
children with epilepsy was 55, and in children without
epilepsy 81. Children with epilepsy had lower IE values
(p\ 0.001).
Variables included in our regression models and their
effect on IE are shown in Table 2 for all included children
and in Table 3 for the subgroup of children with epilepsy.
Univariable regression analysis of all children showed
lower IE values if the child had epilepsy, if the child had
infantile spasms, when a larger number of AEDs was used,
if vigabatrin was used as first or second drug, if corticos-
teroid treatment was used, and if a child was older when it
could walk independently. IE values were higher when
seizure onset was at a later age, and when treatment suc-
cess was achieved by the first AED. No significant effect of
mutation in TSC1 or TSC2 was found.
In a multivariable regression analysis including all
variables listed in Table 2, a later age at seizure onset was
the only variable that had a significant effect on IE. A delay
of seizure onset of 12 months would mean an increase in
IE of 14.0 points.
To assess predictive effects in children with epilepsy
only, analyses were repeated excluding all children without
epilepsy. Analysis of 88 children with epilepsy showed
Table 1 Description of data from all children (n = 102), and the subgroup of children with epilepsy (n = 88)
Variable All children (n = 102),
number (%)/median (IQR)
Children with epilepsy (n = 88),
number (%)/median (IQR)
Gender male 53 (52) 46 (52)
Age at cognitive testing (years) 8.2 (4.7–12.0) 8.0 (4.0–11.9)
Intelligence equivalent (IE) 59 (39–78) 55 (30–73)
Mutation
TSC1 27 (27) 21 (24)
TSC2 67 (66) 60 (68)
NMI 6 (6) 5 (6)
Epilepsy 88 (86) 88 (100)
Infantile spasms 37 (36) 37 (42)
Age at seizure onset (months) 8 (4–24) 6 (3–16)
Number of AEDs used 1 (0–3) 2 (1–4)
Success of first AED 75 (74) 61 (70)
Vigabatrin used
First AED 33 (32) 19 (22)
Second AED or later 30 (29) 30 (34)
Never used 39 (38) 39 (44)
Corticosteroid treatment 5 (5) 5 (6)
Age of walking independently (months) 18 (14–22) 18 (14–23)
IQR inter quartile range, NMI no mutation identified, AED anti-epileptic drug
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lower IE values if the child had infantile spasms, when a
larger number of AEDs was used, if vigabatrin was used as
first or second drug, if corticosteroid treatment was used,
and if a child was older when it could walk independently.
IE values were higher when seizure onset was at a later
age. No correlation was found between IE and mutation in
TSC1 or TSC2. The multivariable analysis showed that
only a later age at seizure onset was independently pre-
dictive of IE. A delay of seizure onset of 12 months would
mean an IE increase of 14.2 points in these children.
The correlation of IE with the age at seizure onset is
shown in Fig. 2. Figure 2a shows the correlation with IE
for all children, in whom 28% of IE variation is explained
by the age at seizure onset. Figure 2b shows the correlation
of IE variation with the age at seizure onset in children who
had their first seizure within the first 24 months of life.
32% of IE variation is explained by age at seizure onset in
this subgroup.
Discussion
In this study we used a multivariable regression model to
confirm factors that were previously reported to contribute
to IE, and to identify new factors contributing to IE. We
specifically focused on the possible determinants in the first
24 months of life. We found that age at seizure onset could
independently predict IE in our cohort of 102 TSC patients.
Our analysis showed a 1.2 points increase of IE for every
month the child does not develop epilepsy. This is an IE
increase of 14 points for every year the child remains
seizure free. This is a clinically relevant increase, as it
could mean the difference between being dependent on
other individuals throughout life, or going to school and
leading an independent life. The variation in IE is
explained for 28% by age at seizure onset in the total
population, and for 32% in a subpopulation of children
with epilepsy. Other factors, including details on the
treatment of epilepsy, were found to be predictors of
cognitive development in a univariable analysis, but had no
significant effect after correcting for the age at seizure
onset. Therefore, we could not make a prediction model for
cognitive development in children with TSC.
Epilepsy is known to negatively influence cognitive
functioning [9]. The age at seizure onset has also been
previously correlated with cognition, and patients suffering
from epilepsy starting in infancy are at high risk of reduced
cognitive abilities. This has also been shown for patients
with TSC [1, 7]. Our study shows that, of all the factors
Fig. 1 Intelligence equivalent (IE) measured by standard cognitive
tests (no epilepsy n = 14, epilepsy n = 88)
Table 2 Analysis results of all children (n = 102)
Variable Univariable b 95% CI p value Multivariable b 95% CI p value
Mutation
TSC1 17.7 -2.0 to 37.4 0.078 5.7 -12.3 to 23.7 0.534
TSC2 -3.3 -21.6 to 15.1 0.728 -3.5 -20.3 to 13.2 0.679
Epilepsy -28.4 -42.3 to -14.6 0.000 -8.8 -28.5 to 10.9 0.383
Infantile spasms -18.3 -28.4 to -8.2 0.000 2.0 -10.0 to 13.9 0.746
Age at seizure onset (months) 1.7 1.3 to 2.2 0.000 1.2 0.4 to 2.0 0.005
Number of AEDs used -6.3 -8.6 to -4.0 0.000 -0.9 -4.7 to 2.9 0.634
Success of first AED 15.7 4.0 to 27.4 0.008 -0.2 -12.3 to 11.8 0.972
Vigabatrin used
First AED -0.9 -12.9 to 11.1 0.881 -3.3 -17.7 to 11.1 0.654
Second AED or later -14.6 -26.9 to -2.3 0.020 -4.5 -17.8 to 8.8 0.509
Never used x x x x x x
Corticosteroid treatment -33.2 -56.1 to -10.3 0.005 -11.8 -34.9 to 11.3 0.318
Age of walking independently (months) -2.1 -3.2 to -0.9 0.000 -0.3 -1.5 to 0.9 0.622
CI confidence interval, AED anti-epileptic drug
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included in our multivariable statistical model, only the age
at seizure onset was an independent predictor of cognitive
development.
Most studies correlating cognitive functioning with
patient-related factors have only used univariable analysis
methods. Our study confirms that most factors related to
epilepsy treatment, for example the number of AEDs and
corticosteroid treatment, are correlated to cognitive func-
tion when analyzed separately. If they are corrected for the
age at seizure onset; however, this effect disappears. This
underscores the importance of multivariable analyses, in
which any association is corrected for possible confound-
ing factors. Our model confirms previous findings from
Jansen et al. [7], showing that factors related to cognitive
development are highly intertwined, and we should be
cautious about giving parents information on the develop-
ment of their child based on studies using univariable
analyses.
Even though studies suggest that early and effective
treatment of epilepsy is beneficial for cognitive develop-
ment [5], the lack of direct significant correlations found in
our analyses is not a new finding. Previous studies in
patients with TSC have also struggled to show better
cognitive development with successful epilepsy treatment,
when trying to find variables independent of other factors
[15]. This might indicate that the response to epilepsy
treatment is dependent on intrinsic factors of the patient,
including the age at seizure onset, and is therefore not an
independent predictor. It is also possible that we did not
use the right epilepsy treatment variables. For our study,
we explored the literature and found that most studies used
response to AEDs and AED resistance as variables to
correlate with IE. We attempted to make these variables
more objective, by including the number of AEDs used,
whether the child used corticosteroids or adrenocorti-
cotropic hormone (ACTH), whether the first AED was
successful (a seizure frequency decrease of at least 50%),
and whether the child used vigabatrin as a first AED, later
during treatment, or never. Furthermore, we explored the
variable ‘time between the first seizure and the first treat-
ment’, as it has been suggested that a treatment delay might
cause a decrease of cognitive capabilities [5]. However, in
our cohort, a treatment delay was mostly present in patients
with a single seizure without an epileptic encephalopathy
on EEG. Treatment delay was, therefore, not a marker of
duration of uncontrolled epilepsy, and an AED was usually
started when a second seizure occurred. Therefore, a long
period between first and second seizure might in our cohort
be a marker for a good prognosis. A delay in treatment of
infantile spasms may still be an independent prognostic
factor. However, due to the small number of children with
infantile spasms in our study population, we could not
analyze this group separately.
Besides factors related to epilepsy and epilepsy treat-
ment, several other factors have also been correlated with
cognitive functioning, including if the patient had a
mutation in TSC1 or TSC2 [14]. A recent study made a new
classification of mutations based on the length of the amino
acid tail at the C-terminal in patients with a frameshift or
nonsense mutation. A longer C-terminal was correlated
with a decreased cognitive functioning in patients with a
TSC1 mutation, and increased cognitive function in
patients with a TSC2 mutation [16]. In contrast to these
findings, in a univariable analysis of our cohort, TSC1
mutations leaving a longer C-terminal tail seemed to cor-
relate with better cognitive functioning. For TSC2 muta-
tions we could not find a relationship with the length of the
C-terminal tail. However, the number of patients with a
Table 3 Analysis results of children with epilepsy (n = 88)
Variable Univariable b 95% CI p value Multivariable b 95% CI p value
Mutation
TSC1 16.6 -4.4 to 37.5 0.121 4.1 -16.2 to 24.4 0.691
TSC2 -4.2 -23.4 to 15.0 0.666 -6.1 -24.8 to 12.6 0.523
Infantile spasms -13.4 -24.0 to -2.8 0.013 1.7 -10.9 to 14.2 0.796
Age at seizure onset (months) 1.6 1.1 to 2.2 0.000 1.2 0.3 to 2.0 0.007
Number of AEDs used -5.3 -7.8 to -2.8 0.000 -0.9 -4.8 to 3.1 0.661
Succes first AED 11.1 -0.8 to 23.1 0.068 0.5 -12.2 to 13.2 0.937
Vigabatrin used
First AED -16.3 -29.9 to -2.6 0.019 -3.2 -18.3 to 11.9 0.675
Second AED or later -14.6 -26.4 to -2.7 0.016 -4.9 -18.9 to 9.0 0.491
Never used x x x x x x
Corticosteroid treatment -29.3 -51.9 to -6.8 0.011 -11.8 -36.0 to 12.4 0.340
Age of walking independently (months) -2.0 -3.2 to -0.8 0.001 -0.2 -1.6 to 1.3 0.828
CI confidence interval AED anti-epileptic drug
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frameshift or nonsense mutation in our cohort was only 32.
Larger cohorts may shed light on the relation between the
C-terminal tail and cognitive functioning.
Another factor that has been previously correlated with
cognitive function is lesion burden on brain MRI, including
the number of cortical tubers, the proportion of brain
occupied by tubers and the integrity of white matter
[11, 13]. We recognize that this lesion burden plays an
important role in brain function, and is therefore likely
important in the cognitive development of children with
TSC. Unfortunately we did not have MRI data of all
children in our study cohort, and could, therefore, not
include data on lesion burden in our statistical analysis.
Several ongoing studies are collecting data on epilepsy and
MRI, including the EPISTOP study (clinicaltrials.gov
NCT02098759). This study aims to find biomarkers for
epileptogenesis, and will investigate the effect of treatment
on epilepsy and cognitive functioning before seizures arise.
Combining data from these studies allows the generation of
a more detailed predictive model.
We have chosen to use data on possible determinants in
the first 24 months of life, since we intended to search for
factors in early life that could be correlated with IE. These
could aid physicians in making a cautious prediction about
the impact of epilepsy and the cognitive outcome of a
child. Cognitive development in patients with TSC is very
difficult to predict. It would be useful for parents to have an
indication of the future abilities of their child, to find the
appropriate support and schooling for their child. Finding
predictors can also help select children at risk for cognitive
problems for future intervention trials.
Our study had several limitations. The children in our
study were all treated at a university hospital, which may
have introduced a bias towards children who were more
severely affected by TSC. Furthermore, some children
were treated before the current treatment guidelines for
TSC related epilepsy were introduced [3, 10], which might
have led to treatment regimens that were not up to the
current treatment standard. In addition, our analyses were
not able to distinguish between correlation and causality.
The question remains whether an early age at seizure onset
causes decreased cognitive functioning, or whether the two
are caused by the same intrinsic mechanism.
In conclusion, our study shows that, in our study pop-
ulation of 102 children with TSC, age at seizure onset is the
only factor that independently predicts cognitive func-
tioning later in life. Finding appropriate markers of early
development that can help to predict the cognitive outcome
of children with TSC could aid parents and physicians in
finding the appropriate support and schooling for these
patients, to optimize their chances and outcome in life.
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